Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir

International Journal of STD and AIDS

Volumn 22, Issue 1, 2011, Pages 11-14

  Caswell, R J ^a   Phillips, D ^b   Chaponda, M ^c   Khoo, S H ^c   Taylor, G P ^d   Ghanem, M ^e   Poulton, M ^f   Welch, J ^g   Gibbons, S ^b   Jackson, V ^g   Lambert, J S ^h,i  

^a Teaching Primary Care Trust   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e Northamptonshire Healthcare NHS Trust   (United Kingdom)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g ROTUNDA HOSPITAL   (Ireland)

^h MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

ⁱ UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

HIV; Lopinavir; Pharmacokinetics; Pregnancy; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ABACAVIR PLUS NEVIRAPINE; ABACAVIR PLUS TENOFIVIR; ABACAVIR PLUS ZIDOVUDINE; DIDANOSINE; DIDANOSINE PLUS ABACAVIR; DIDANOSINE PLUS ABACAVIR PLUS LAMIVUDINE PLUS SAQUINAVIR; DIDANOSINE PLUS LAMIVUDINE; DIDANOSINE PLUS TENOFOVIR; DIDANOSINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; SAQUINAVIR; SAQUINAVIR PLUS TENOFOVIR PLUS ABACAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR PLUS LAMIVUDINE PLUS STAVUDINE; TENOFOVIR PLUS SAQUINAVIR; TENOFOVIR PLUS ZIDOVUDINE; TENOFOVIR PLUS ZIDOVUDINE PLUS LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PATIENT COMPLIANCE; PHARMACIST; PREGNANT WOMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD; WILD TYPE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; LOPINAVIR; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952268398     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009184     Document Type: Article

References (17)

1. Intercollegiate Working Party. Reducing Mother to Child Transmission of HIV Infection in the United Kingdom. London: Royal College of Paediatrics and Child Health, 2006
2. Rakhmanina N, van den Anker JN, Soldin SJ. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther Drug Monitor 2004;26:110-5 (Pubitemid 38501202)
3. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007;2:1019-26 (Pubitemid 46684333)
4. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48:430-6 (Pubitemid 38141698)
5. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931-9 (Pubitemid 44427610)
6. Lyons F, Lechelt M, Magaya V, et al. Adequate trough lopinavir levels with standard dosing in pregnancy. Poster Presentation Abstract 709 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006
7. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Life Sci 2005;829:82-90 (Pubitemid 41773468)
8. la Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiviral agents. Rev Antivir Ther 2006;3:5-14
9. Gutiérrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavircontaining regimens. J Acquir Immune Defic Syndr 2003;33:594-600 (Pubitemid 36975846)
10. Seminari E, Gentilini G, Galli L, et al. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J Antimicrob Chemother 2005;56:790-2 (Pubitemid 41487788)
11. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIVAssociation guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452-502
12. Best B, Stek A, Hu C, et al. High-dose lopinavir and standard dose emtricitabine pharmacokinetics during pregnancy and postpartum. Poster Presentation Abstract 629 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008
13. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough concentrations in a group of pregnant women on lopinavir, ritonavir, zidovudine and lamivudine. Res Lett AIDS 2007;21:643-7
14. Bouillon-Pichault M, Jullien V, Azria1 E, et al. Lopinavir population pharmacokinetics on HIV-infected pregnant women. Poster Presentation Abstract 628 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008
15. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimisation of protease inhibitors and non-nucleoside transcriptase inhibitors (POPIN) - a randomised controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006;41:461-7
16. Burger DM, Aarnoutse RE, Hugen PWH. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002;15:17-22 (Pubitemid 34112388)
17. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006;42:1189-96